Compare RAVE & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAVE | VERU |
|---|---|---|
| Founded | 1958 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.4M | 36.8M |
| IPO Year | 1995 | 1996 |
| Metric | RAVE | VERU |
|---|---|---|
| Price | $2.45 | $2.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | 23.9K | ★ 49.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | $15,120,000.00 | ★ $16,296,958.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.78 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.01 | $0.36 |
| 52 Week High | $3.75 | $4.59 |
| Indicator | RAVE | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 25.47 | 41.54 |
| Support Level | N/A | $2.15 |
| Resistance Level | $3.49 | $2.70 |
| Average True Range (ATR) | 0.14 | 0.12 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 2.00 | 22.51 |
Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.